New Multicenter Study Highlights Utility of Daxor’s Blood Volume Analysis in Heart Failure Care
Daxor (Nasdaq: DXR) announces a multicenter study published in the Journal of Cardiac Failure demonstrating the superiority of their Blood Volume Analysis (BVA) technology in heart failure treatment. The study, involving 255 heart failure patients across Mayo Clinic, Duke University Medical Center, and Baptist Hospital in Memphis, revealed that BVA outperforms standard hemodynamic measurements in assessing heart failure volume status.
The research, titled 'Patient Sex Impacts Volume Phenotypes and Hemodynamics in Chronic Heart Failure,' highlighted three key findings: hemodynamic pressure measures are less accurate compared to BVA, the technology enables more precise anemia diagnosis, and sex-specific volume differences require individualized treatment approaches. The study confirms BVA's 98% accuracy in volume measurement, establishing it as a important tool for precise heart failure diagnosis and treatment.
Daxor (Nasdaq: DXR) annuncia uno studio multicentrico pubblicato nel Journal of Cardiac Failure che dimostra la superiorità della loro tecnologia di Analisi del Volume Sanguigno (BVA) nel trattamento dell'insufficienza cardiaca. Lo studio, che ha coinvolto 255 pazienti con insufficienza cardiaca presso la Mayo Clinic, il Duke University Medical Center e il Baptist Hospital di Memphis, ha rivelato che la BVA supera le misurazioni emodinamiche standard nella valutazione dello stato del volume cardiaco.
La ricerca, intitolata 'Il sesso del paziente influisce sui fenotipi di volume e sull'emodinamica nell'insufficienza cardiaca cronica', ha evidenziato tre risultati chiave: le misurazioni della pressione emodinamica sono meno accurate rispetto alla BVA, la tecnologia consente una diagnosi dell'anemia più precisa e le differenze di volume specifiche per il sesso richiedono approcci terapeutici individualizzati. Lo studio conferma l'accuratezza del 98% della BVA nella misurazione del volume, stabilendola come uno strumento importante per una diagnosi e un trattamento precisi dell'insufficienza cardiaca.
Daxor (Nasdaq: DXR) anuncia un estudio multicéntrico publicado en el Journal of Cardiac Failure que demuestra la superioridad de su tecnología de Análisis de Volumen Sanguíneo (BVA) en el tratamiento de la insuficiencia cardíaca. El estudio, que involucró a 255 pacientes con insuficiencia cardíaca en la Clínica Mayo, el Centro Médico de la Universidad de Duke y el Baptist Hospital en Memphis, reveló que la BVA supera las mediciones hemodinámicas estándar en la evaluación del estado del volumen cardíaco.
La investigación, titulada 'El sexo del paciente impacta en los fenotipos de volumen y hemodinámica en la insuficiencia cardíaca crónica', destacó tres hallazgos clave: las medidas de presión hemodinámica son menos precisas en comparación con la BVA, la tecnología permite un diagnóstico más preciso de la anemia y las diferencias de volumen específicas por sexo requieren enfoques de tratamiento individualizados. El estudio confirma la exactitud del 98% de la BVA en la medición del volumen, estableciéndola como una herramienta importante para un diagnóstico y tratamiento precisos de la insuficiencia cardíaca.
Daxor (Nasdaq: DXR)는 심부전 치료에서 혈액량 분석(BVA) 기술의 우수성을 입증하는 다센터 연구를 Journal of Cardiac Failure에 발표했습니다. 이 연구는 Mayo Clinic, Duke University Medical Center 및 Memphis의 Baptist Hospital에서 255명의 심부전 환자를 포함하였으며, BVA가 심부전의 용적 상태를 평가하는 데 있어 표준 혈행역학적 측정을 초월한다는 결과를 보여주었습니다.
연구 제목은 '환자의 성별이 만성 심부전에서의 용적 표현형과 혈행역학에 미치는 영향'으로, 세 가지 주요 발견을 강조했습니다: 혈행역학적 압력 측정이 BVA에 비해 덜 정확하며, 이 기술이 더 정밀한 빈혈 진단을 가능하게 하고, 성별에 따른 용적 차이가 개별화된 치료 접근을 필요로 한다는 것입니다. 이 연구는 BVA의 98% 정확성을 확인하며, 심부전의 정확한 진단과 치료를 위한 중요한 도구로 자리매김하고 있습니다.
Daxor (Nasdaq: DXR) annonce une étude multicentrique publiée dans le Journal of Cardiac Failure démontrant la supériorité de sa technologie d'analyse du volume sanguin (BVA) dans le traitement de l'insuffisance cardiaque. L'étude, impliquant 255 patients souffrant d'insuffisance cardiaque à la Mayo Clinic, au Duke University Medical Center et au Baptist Hospital de Memphis, a révélé que la BVA surpasse les mesures hémodynamiques standard dans l'évaluation du statut volumique cardiaque.
La recherche, intitulée 'Le sexe du patient impacte les phénotypes de volume et l'hémodynamique dans l'insuffisance cardiaque chronique', a mis en lumière trois résultats clés : les mesures de pression hémodynamique sont moins précises par rapport à la BVA, la technologie permet un diagnostic de l'anémie plus précis, et les différences de volume spécifiques au sexe nécessitent des approches de traitement individualisées. L'étude confirme l'exactitude de 98% de la BVA dans la mesure du volume, établissant cet outil comme essentiel pour un diagnostic et un traitement précis de l'insuffisance cardiaque.
Daxor (Nasdaq: DXR) kündigt eine multizentrische Studie an, die im Journal of Cardiac Failure veröffentlicht wurde und die Überlegenheit ihrer Blutvolumenanalyse (BVA)-Technologie bei der Behandlung von Herzinsuffizienz demonstriert. Die Studie, an der 255 Herzinsuffizienzpatienten der Mayo Clinic, des Duke University Medical Center und des Baptist Hospital in Memphis teilnahmen, zeigte, dass die BVA bei der Beurteilung des Volumenstatus bei Herzinsuffizienz besser abschneidet als die Standardmessungen der Hämodynamik.
Die Forschung mit dem Titel 'Das Geschlecht des Patienten beeinflusst Volumenphänotypen und Hämodynamik bei chronischer Herzinsuffizienz' hob drei wichtige Erkenntnisse hervor: Hämodynamische Druckmessungen sind im Vergleich zur BVA weniger genau, die Technologie ermöglicht eine genauere Diagnose von Anämie, und geschlechtsspezifische Volumendifferenzen erfordern individualisierte Behandlungsansätze. Die Studie bestätigt die 98% Genauigkeit der BVA bei der Volumenmessung und etabliert sie als wichtiges Werkzeug für eine präzise Diagnose und Behandlung von Herzinsuffizienz.
- Published study in prestigious Journal of Cardiac Failure validates BVA technology
- Large-scale validation across three major medical institutions
- BVA demonstrates 98% accuracy in volume measurement
- Technology proven superior to standard hemodynamic measurements
- None.
Insights
This peer-reviewed multicenter study published in the Journal of Cardiac Failure represents a significant clinical validation for Daxor's BVA technology, with substantial implications for both the company's market position and potential revenue growth. The research's scope and prestigious institutional participation (Mayo Clinic, Duke University Medical Center, and Baptist Hospital) provide robust credibility to BVA's clinical utility.
The study's findings carry particular weight in the $11.8 billion heart failure diagnostics market. By demonstrating that traditional pressure-based measurements are inadequate surrogates compared to BVA's 98% accuracy rate, Daxor positions itself to potentially capture a larger share of this growing market. The ability to detect true anemia and sex-specific volume differences addresses critical unmet needs in personalized heart failure management.
From a market perspective, several factors amplify this study's significance:
- The research validates BVA as a superior diagnostic tool, potentially accelerating insurance coverage and reimbursement decisions
- Multi-center validation typically accelerates clinical adoption and inclusion in treatment guidelines
- Improved diagnostic accuracy could reduce hospital readmissions and associated penalties under Medicare's Hospital Readmissions Reduction Program
- The focus on personalized treatment approaches aligns with current healthcare trends toward precision medicine
The study's emphasis on BVA's superior accuracy in volume assessment could drive increased adoption among healthcare providers seeking to optimize heart failure treatment outcomes and reduce costs associated with misdiagnosis or suboptimal treatment. This positions Daxor favorably for potential market share expansion in the growing cardiovascular diagnostics sector.
Research Published in the Prestigious Journal of Cardiac Failure From Three Institutions
Oak Ridge, TN, Feb. 13, 2025 (GLOBE NEWSWIRE) -- Daxor Corporation (Nasdaq: DXR), the global leader in blood volume measurement technology, today announces a multicenter study published in the prestigious Journal of Cardiac Failure reporting pivotal insights for effective heart failure treatment through the use of Daxor’s Blood Volume Analysis (BVA). The study demonstrates how BVA outperforms standard hemodynamic measurements in assessing heart failure volume status, while highlighting its unique capability to detect anemia, a crucial factor for effective treatment.
The research, titled, "Patient Sex Impacts Volume Phenotypes and Hemodynamics in Chronic Heart Failure," analyzed data from 255 heart failure patients across three major medical institutions: Mayo Clinic in Rochester, Duke University Medical Center, and Baptist Hospital in Memphis. Each patient underwent both BVA and pressure assessment.
The study revealed several critical findings:
- Commonly used hemodynamic pressure measures are inaccurate surrogates compared to direct blood volume analysis with Daxor BVA.
- BVA enables more accurate diagnosis of true anemia which is a key guideline target of care.
- Sex-specific volume differences as illuminated by BVA require individualized treatment approaches.
"Pressure is not volume,” commented Marat Fudim, MD, MPH, the study's principal investigator. "These clinically significant differences underscore the importance of distinguishing individual volume profiles to help guide the most appropriate volume-management strategies and avoid potentially deleterious outcomes.”
Jonathan Feldschuh, Daxor’s Chief Scientific Officer further commented, “Volume management is the cornerstone of heart failure care. This study confirms the superior accuracy of BVA over commonly used pressure-based proxies. Effective treatment starts with precise diagnosis—BVA delivers it with
About Daxor Corporation
Daxor Corporation (Nasdaq: DXR), is the global leader in blood volume measurement technology focused on blood volume testing innovation. We developed and market the BVA-100® (Blood Volume Analyzer), the only diagnostic blood test cleared by the FDA to provide safe, accurate, objective quantification of blood volume status and composition compared to patient-specific norms. Over 65,000+ tests have been performed at leading hospital centers across the U.S., enhancing hospital performance metrics in a broad range of surgical and medical conditions, including significantly reducing mortality and readmissions in heart failure and critical care. Daxor has several ongoing trials in the areas of heart failure treatment with support from the NIH and is under contract developing analyzers to improve combat casualty care with the U.S. Department of Defense. Daxor's mission is to advance healthcare by enabling optimal fluid management with blood volume analysis. Daxor’s vision is optimal blood volume for all. For more information, please visit our website at Daxor.com. Sign up to receive news on Daxor’s innovative technology HERE.
Forward-Looking Statements
Certain statements in this release may include forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including without limitation, statements regarding the impact of hiring sales staff and expansion of our distribution channels. Forward-looking statements are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Many factors could cause actual future events to differ materially from the forward-looking statements in this release, including, without limitation, those risk associated with our post-market clinical data collection activities, benefits of our products to patients, our expectations with respect to product development and commercialization efforts, our ability to increase market and physician acceptance of our products, potentially competitive product offerings, intellectual property protection, FDA regulatory actions, our ability to integrate acquired businesses, our expectations regarding anticipated synergies with and benefits from acquired businesses, and additional other risks and uncertainties described in our filings with the SEC. Forward-looking statements speak only as of the date when made. Daxor does not assume any obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events or otherwise.
Investor Relations Contact:
Bret Shapiro
Sr. Managing Partner, CORE IR
1-516-222-2560
brets@coreir.com
FAQ
What are the key findings of DXR's multicenter blood volume study?
How many patients were involved in DXR's heart failure study?
What is the accuracy rate of Daxor's BVA technology?
Which medical institutions participated in DXR's blood volume study?
How does DXR's Blood Volume Analysis compare to traditional methods?
